OBJECTIVES: : The aim of the study was to evaluate UDP-glucuronyltransferase activity and the pharmacokinetics of a single oral dose of acetaminophen (APAP) in children with nonalcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: : Twelve boys 10 to 17 years old with biopsy-proven NAFLD and 12 age- and sex-matched controls without NAFLD were recruited. Following administration of a single oral dose of APAP (5 mg/kg, maximum 325 mg), APAP and its glucuronide metabolite (APAP-G) were measured in plasma, urine, and sputum at various intervals up to 24 hours. The activity of UDP-glucuronyltransferase was estimated by the plasma ratio of APAP-G to APAP at 4 hours. RESULTS: : Following administration of APAP, children with NAFLD had significantly higher concentrations of APAP-G in serum (P = 0.0071) and urine (P = 0.0210) compared with controls. No significant differences in APAP pharmacokinetics parameters were observed between the 2 groups. CONCLUSIONS: : APAP glucuronidation is altered in children with fatty liver disease. Despite the altered disposition of this metabolite, the pharmacokinetics of a single 5 mg/kg dose of APAP is the same in children with NAFLD as in children with normal liver function.
OBJECTIVES: : The aim of the study was to evaluate UDP-glucuronyltransferase activity and the pharmacokinetics of a single oral dose of acetaminophen (APAP) in children with nonalcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: : Twelve boys 10 to 17 years old with biopsy-proven NAFLD and 12 age- and sex-matched controls without NAFLD were recruited. Following administration of a single oral dose of APAP (5 mg/kg, maximum 325 mg), APAP and its glucuronide metabolite (APAP-G) were measured in plasma, urine, and sputum at various intervals up to 24 hours. The activity of UDP-glucuronyltransferase was estimated by the plasma ratio of APAP-G to APAP at 4 hours. RESULTS: : Following administration of APAP, children with NAFLD had significantly higher concentrations of APAP-G in serum (P = 0.0071) and urine (P = 0.0210) compared with controls. No significant differences in APAP pharmacokinetics parameters were observed between the 2 groups. CONCLUSIONS: : APAP glucuronidation is altered in children with fatty liver disease. Despite the altered disposition of this metabolite, the pharmacokinetics of a single 5 mg/kg dose of APAP is the same in children with NAFLD as in children with normal liver function.
Authors: Naga Chalasani; J Christopher Gorski; Maleeha S Asghar; Ali Asghar; Brian Foresman; Stephen D Hall; David W Crabb Journal: Hepatology Date: 2003-03 Impact factor: 17.425
Authors: Maurice G Emery; Jeannine M Fisher; Jenny Y Chien; Evan D Kharasch; E Patchen Dellinger; Kris V Kowdley; Kenneth E Thummel Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Z G Dong; J Y Hong; Q A Ma; D C Li; J Bullock; F J Gonzalez; S S Park; H V Gelboin; C S Yang Journal: Arch Biochem Biophys Date: 1988-05-15 Impact factor: 4.013
Authors: Caroline D van der Marel; Brian J Anderson; Richard A van Lingen; Nicholas H G Holford; Marien A L Pluim; Frank G A Jansman; John N van den Anker; Dick Tibboel Journal: Eur J Clin Pharmacol Date: 2003-05-22 Impact factor: 2.953
Authors: Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2012-05-01 Impact factor: 6.447
Authors: Mark J Canet; Matthew D Merrell; Rhiannon N Hardwick; Amy M Bataille; Sarah N Campion; Daniel W Ferreira; Stavra A Xanthakos; Jose E Manautou; H Hesham A-Kader; Robert P Erickson; Nathan J Cherrington Journal: Drug Metab Dispos Date: 2015-03-18 Impact factor: 3.922
Authors: Kathryn E Kyler; Jonathan Wagner; Chelsea Hosey-Cojocari; Kevin Watt; Valentina Shakhnovich Journal: Paediatr Drugs Date: 2019-10 Impact factor: 3.022
Authors: Hui Li; Mark J Canet; John D Clarke; Dean Billheimer; Stavra A Xanthakos; Joel E Lavine; Robert P Erickson; Nathan J Cherrington Journal: Drug Metab Dispos Date: 2017-10-06 Impact factor: 3.922